Premarket Mover: Kinnate Biopharma Inc (KNTE) Down 12.35%

Tuesday, September 19, 2023 06:47 AM | InvestorsObserver Analysts

Mentioned in this article

Premarket Mover: Kinnate Biopharma Inc (KNTE) Down 12.35%

Kinnate Biopharma Inc (KNTE) has fallen Tuesday morning, with the stock falling -12.35% in pre-market trading to 1.49. KNTE's short-term technical score of 14 indicates that the stock has traded less bullishly over the last month than 86% of stocks on the market. In the Biotechnology industry, which ranks 132 out of 146 industries, the stock ranks higher than 27% of stocks. Kinnate Biopharma Inc has fallen 17.87% over the past month, closing at $2.06 on August 22. During this period of time, the stock fell as low as $1.70 and as high as $2.47. KNTE has an average analyst recommendation of Strong Buy. The company has an average price target of $20.34.

KNTE has an Overall Score of 35. Find out what this means to you and get the rest of the rankings on KNTE!

See Full KNTE Report

Kinnate Biopharma Inc has a Long-Term Technical rank of 3. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 97% of the market scoring higher. In the Biotechnology industry which is number 134 by this metric, KNTE ranks better than 134% of stocks.

Important Dates for Investors in KNTE:

-Kinnate Biopharma Inc is set to release earnings on 2023-11-09. Over the last 12 months, the company has reported EPS of $-2.82. -We do not have a set dividend date for Kinnate Biopharma Inc at this time. Click Here To Get The Full Report on Kinnate Biopharma Inc (KNTE)